BSE Live
Feb 09, 16:01Prev. Close
352.35
Open Price
354.50
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Feb 09, 15:59Prev. Close
349.55
Open Price
350.00
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
| Key Financial Ratios of Medicamen Biotech (in Rs. Cr.) | Mar 10 | Mar 09 | Mar 08 | Mar 07 | Mar 06 | |
| Per Share Ratios | ||||||
| Basic EPS (Rs.) | 5.15 | 1.78 | 1.96 | 1.95 | 1.94 | |
| Diluted EPS (Rs.) | 5.15 | 1.78 | 1.96 | 1.95 | 1.94 | |
| Cash EPS (Rs.) | 6.66 | 3.12 | 3.11 | 2.80 | 2.72 | |
| Book Value [ExclRevalReserve]/Share (Rs.) | 21.06 | 16.78 | 15.00 | 13.05 | 11.09 | |
| Book Value [InclRevalReserve]/Share (Rs.) | 21.06 | 16.78 | 15.00 | 13.05 | 11.09 | |
| Dividend / Share(Rs.) | 0.75 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Revenue from Operations/Share (Rs.) | 131.59 | 111.81 | 99.62 | 78.27 | 68.36 | |
| PBDIT/Share (Rs.) | 10.74 | 5.41 | 5.57 | 4.10 | 3.98 | |
| PBIT/Share (Rs.) | 9.23 | 4.07 | 4.41 | 3.25 | 3.20 | |
| PBT/Share (Rs.) | 7.65 | 2.27 | 2.43 | 2.37 | 2.32 | |
| Net Profit/Share (Rs.) | 5.15 | 1.78 | 1.96 | 1.95 | 1.94 | |
| Profitability Ratios | ||||||
| PBDIT Margin (%) | 8.16 | 4.83 | 5.59 | 5.23 | 5.82 | |
| PBIT Margin (%) | 7.01 | 3.63 | 4.42 | 4.14 | 4.68 | |
| PBT Margin (%) | 5.81 | 2.03 | 2.43 | 3.02 | 3.38 | |
| Net Profit Margin (%) | 3.91 | 1.59 | 1.96 | 2.49 | 2.83 | |
| Return on Networth / Equity (%) | 24.45 | 10.62 | 13.03 | 14.95 | 17.44 | |
| Return on Capital Employed (%) | 20.27 | 8.17 | 8.68 | 8.88 | 11.53 | |
| Return on Assets (%) | 6.89 | 3.00 | 2.91 | 3.24 | 4.41 | |
| Total Debt/Equity (X) | 0.78 | 0.68 | 1.16 | 1.23 | 0.85 | |
| Asset Turnover Ratio (%) | 176.15 | 188.46 | 148.57 | 130.21 | 156.08 | |
| Liquidity Ratios | ||||||
| Current Ratio (X) | 0.97 | 0.95 | 1.00 | 1.06 | 1.10 | |
| Quick Ratio (X) | 0.74 | 0.69 | 0.77 | 0.64 | 0.82 | |
| Inventory Turnover Ratio (X) | 11.58 | 11.71 | 9.64 | 4.87 | 9.04 | |
| Dividend Payout Ratio (NP) (%) | 14.56 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Dividend Payout Ratio (CP) (%) | 11.26 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Earnings Retention Ratio (%) | 85.44 | 100.00 | 100.00 | 100.00 | 100.00 | |
| Cash Earnings Retention Ratio (%) | 88.74 | 100.00 | 100.00 | 100.00 | 100.00 | |
| Valuation Ratios | ||||||
| Enterprise Value (Cr.) | 30.73 | 15.87 | 23.19 | 24.34 | 18.14 | |
| EV/Net Operating Revenue (X) | 0.30 | 0.18 | 0.30 | 0.40 | 0.34 | |
| EV/EBITDA (X) | 3.71 | 3.80 | 5.39 | 7.69 | 5.90 | |
| MarketCap/Net Operating Revenue (X) | 0.19 | 0.09 | 0.14 | 0.21 | 0.21 | |
| Retention Ratios (%) | 85.43 | 100.00 | 100.00 | 100.00 | 100.00 | |
| Price/BV (X) | 1.18 | 0.62 | 0.90 | 1.24 | 1.29 | |
| Price/Net Operating Revenue | 0.19 | 0.09 | 0.14 | 0.21 | 0.21 | |
| Earnings Yield | 0.21 | 0.17 | 0.15 | 0.12 | 0.14 |
26.11.2025
Medicamen Bio Consolidated September 2025 Net Sales at Rs 47.17 crore, up 5.42% Y-o-Y
24.11.2025
Medicamen Bio Standalone September 2025 Net Sales at Rs 42.23 crore, down 1.44% Y-o-Y
09.09.2025
Medicamen Bio Standalone June 2025 Net Sales at Rs 38.45 crore, down 7.31% Y-o-Y
11.06.2025
Medicamen Bio Standalone March 2025 Net Sales at Rs 26.00 crore, down 42.24% Y-o-Y
26.11.2025
Medicamen Bio Consolidated September 2025 Net Sales at Rs 47.17 crore, up 5.42% Y-o-Y
24.11.2025
Medicamen Bio Standalone September 2025 Net Sales at Rs 42.23 crore, down 1.44% Y-o-Y
09.09.2025
Medicamen Bio Standalone June 2025 Net Sales at Rs 38.45 crore, down 7.31% Y-o-Y
11.06.2025
Medicamen Bio Standalone March 2025 Net Sales at Rs 26.00 crore, down 42.24% Y-o-Y